LEXINGTON, Mass., March 2 /PRNewswire/ -- ActivBiotics, Inc. a private biopharmaceutical company focused on high-value chronic and infectious disease markets, today announced that President and Chief Executive Officer Steven C. Gilman, Ph.D. will present at the SG Cowen & Co. 26th Annual Health Care Conference.
The conference will be held from March 6-9, 2006 at The Boston Marriott Copley Place Hotel, Boston, MA. Dr. Gilman's presentation will take place on Thursday, March 9th at 10:00 AM EST.
About the Company
ActivBiotics, Inc., located in Lexington, MA is a private biopharmaceutical company focused on the discovery, development and commercialization of breakthrough antibacterials for high-value chronic and infectious disease markets. The Company's lead product candidate, rifalazil, is undergoing clinical development trials in multiple indications. The Company's lead pre-clinical compound in a pipeline of novel rifamycins, ABI- 0043, shows significant potential for the treatment of infections caused by Gram-positive pathogens, including Chlamydia pneumoniae, Staphylococcus aureus and MRSA (methicillin-resistant Staphylococcus aureus).
Through its wholly owned subsidiary, Metaphore Pharmaceuticals, the Company is also developing a small molecule compound, as well as the class, that mimic the functions of superoxide dismutase, a beneficial human enzyme. The compound M40403 has been studied in Phase 1 and Phase 2 trials in 680 patients and subjects. Current product development efforts are focused on inflammation and diseases related to oxygen free radical toxicity.
For more information on ActivBiotics, please visit our web site at: http://www.activbiotics.com.
ActivBiotics, Inc.CONTACT: Glenn Kazo, Chief Business Officer of ActivBiotics, Inc., +1-781-372-4864, gkazo@activbiotics.com
Web site: http://www.activbiotics.com/
